Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Other Events
Item8.01 Other Events.
On June27, 2017, Dimension Therapeutics, Inc. (the Company)
announced its completion of a strategic review and updates to
corporate priorities in a press release, a copy of which is filed
herewith as Exhibit 99.1 to this Report on Form 8-K and is
incorporated herein by reference.
The Company plans to reorganize its operations to align with its
new priorities focused on the internal efforts on the advancement
of three programs to key clinical milestones. In connection with
the reprioritization, the Company expects to reduce approximately
25% of its workforce to a total of 56 employees, including
workforce reductions and attrition, by December 2017. The Company
expects the reorganization to result in approximately $3.0million
in reduced annualized workforce expenses once the plan is fully
implemented.
Item9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
|
| 99.1 | Press release issued by the Company on June27, 2017. |
Dimension Therapeutics, Inc. ExhibitEX-99.1 2 d609314dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities Initial data from Phase 1/2 clinical trial of DTX301,…To view the full exhibit click here About Dimension Therapeutics, Inc. (NASDAQ:DMTX)
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.